388 related articles for article (PubMed ID: 11984589)
1. ErbB2 is essential in the prevention of dilated cardiomyopathy.
Crone SA; Zhao YY; Fan L; Gu Y; Minamisawa S; Liu Y; Peterson KL; Chen J; Kahn R; Condorelli G; Ross J; Chien KR; Lee KF
Nat Med; 2002 May; 8(5):459-65. PubMed ID: 11984589
[TBL] [Abstract][Full Text] [Related]
2. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy.
Ozcelik C; Erdmann B; Pilz B; Wettschureck N; Britsch S; Hübner N; Chien KR; Birchmeier C; Garratt AN
Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8880-5. PubMed ID: 12072561
[TBL] [Abstract][Full Text] [Related]
3. Essential roles of Her2/erbB2 in cardiac development and function.
Negro A; Brar BK; Lee KF
Recent Prog Horm Res; 2004; 59():1-12. PubMed ID: 14749494
[TBL] [Abstract][Full Text] [Related]
4. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer.
Kauraniemi P; Kallioniemi A
Endocr Relat Cancer; 2006 Mar; 13(1):39-49. PubMed ID: 16601278
[TBL] [Abstract][Full Text] [Related]
5. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.
Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J
Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598
[TBL] [Abstract][Full Text] [Related]
6. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy.
Liu X; Gu X; Li Z; Li X; Li H; Chang J; Chen P; Jin J; Xi B; Chen D; Lai D; Graham RM; Zhou M
J Am Coll Cardiol; 2006 Oct; 48(7):1438-47. PubMed ID: 17010808
[TBL] [Abstract][Full Text] [Related]
7. Neuregulin receptors erbB2 and erbB4 in failing human myocardium -- depressed expression and attenuated activation.
Rohrbach S; Niemann B; Silber RE; Holtz J
Basic Res Cardiol; 2005 May; 100(3):240-9. PubMed ID: 15685397
[TBL] [Abstract][Full Text] [Related]
8. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
Harris LN; Yang L; Liotcheva V; Pauli S; Iglehart JD; Colvin OM; Hsieh TS
Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
[TBL] [Abstract][Full Text] [Related]
9. Interaction and inhibitory cross-talk between endothelin and ErbB receptors in the adult heart.
Chung KY; Walker JW
Mol Pharmacol; 2007 Jun; 71(6):1494-502. PubMed ID: 17332141
[TBL] [Abstract][Full Text] [Related]
10. ErbB2 pathways in heart and neural diseases.
Garratt AN; Ozcelik C; Birchmeier C
Trends Cardiovasc Med; 2003 Feb; 13(2):80-6. PubMed ID: 12586444
[TBL] [Abstract][Full Text] [Related]
11. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
[TBL] [Abstract][Full Text] [Related]
12. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
[TBL] [Abstract][Full Text] [Related]
13. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi M; Romano A; Curia MC; Muraro R; Fedi P; Aaronson SA; Di Fiore PP; Kraus MH
Oncogene; 1995 May; 10(9):1813-21. PubMed ID: 7538656
[TBL] [Abstract][Full Text] [Related]
14. Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth.
Andrechek ER; White D; Muller WJ
Oncogene; 2005 Jan; 24(5):932-7. PubMed ID: 15580295
[TBL] [Abstract][Full Text] [Related]
15. HER2 testing: a review of detection methodologies and their clinical performance.
Laudadio J; Quigley DI; Tubbs R; Wolff DJ
Expert Rev Mol Diagn; 2007 Jan; 7(1):53-64. PubMed ID: 17187484
[TBL] [Abstract][Full Text] [Related]
16. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
[TBL] [Abstract][Full Text] [Related]
17. erbB2 is required for G protein-coupled receptor signaling in the heart.
Negro A; Brar BK; Gu Y; Peterson KL; Vale W; Lee KF
Proc Natl Acad Sci U S A; 2006 Oct; 103(43):15889-93. PubMed ID: 17043217
[TBL] [Abstract][Full Text] [Related]
18. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
Jani JP; Finn RS; Campbell M; Coleman KG; Connell RD; Currier N; Emerson EO; Floyd E; Harriman S; Kath JC; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Ralston S; Rossi AM; Steyn SJ; Wagner L; Winter SM; Bhattacharya SK
Cancer Res; 2007 Oct; 67(20):9887-93. PubMed ID: 17942920
[TBL] [Abstract][Full Text] [Related]
19. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer.
Dressman MA; Baras A; Malinowski R; Alvis LB; Kwon I; Walz TM; Polymeropoulos MH
Cancer Res; 2003 May; 63(9):2194-9. PubMed ID: 12727839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
